Heart Research Australia is encouraging Australians to wear red and donate during February, to raise awareness for heart disease and funds for life-saving research.
A trial has found that heart attacks and the need for coronary stenting or bypass surgery reduced by 30% in patients taking low-dose colchicine, a drug commonly used to treat gout.
The team of doctors used stereotactic ablative body radiotherapy to treat a patient with a life-threatening arrhythmia known as ventricular tachycardia.
Australians living with symptoms of severe aortic stenosis will now have access to a minimally invasive heart treatment that was previously reserved for only the sickest patients.
A research project underway in western Sydney could see marked improvements for patients with atrial fibrillation.
A University of Newcastle study has revealed that heart patients with a history of cancer are less likely to receive the heart medications they need.
A new heart transplant method means that a donated heart can now be transported and preserved for longer than previously possible.
An Australian-developed anti-clotting drug could treat one of the most devastating, life-threatening complications of COVID-19 — microscopic blood clots.
Tens of thousands of Australians with chronic diseases are putting themselves at risk by missing vital visits to their GP.
Researchers from Monash University are developing a device to safely and effectively treat the most common cardiovascular disease: atherosclerosis, or narrowing of the arteries.
The Heart Foundation is urging those with conditions such as heart failure, and those aged 65 years and over, to be aware of the risks to their health and the need to protect themselves.
Unlike the Ganesan study, published in Internal Medicine Journal, GenesisCare cardiologists have found marked variation in complication rates for cardiac device implantation.
Public and private hospitals have similar safety outcomes for pacemaker and defibrillator implant surgeries, according to a comparative study.
The release of new European guidelines on dyslipidaemias has called Australia’s LDL-C targets into question.
Assessment times for patients presenting with chest pains can be safely reduced, easing pressure on often overcrowded emergency departments.